bioRxivPharmacology & Toxicology
Quantification of phosphonate drugs by 1H-31P HSQC shows that rats are better models of primate drug exposure than mice
Y. Barekatain, S. Khadka, K. Harris, J. Delacerda, V. C. Yan, K.-C. Chen, C.-D. Pham, M. N. Uddin, R. Avritcher, E. J. Eisenberg, R. Kalluri, S. W. Millward, F. L. Muller
Abstract
The phosphonate group is a key pharmacophore in many anti-viral, anti-microbial, and anti-neoplastic drugs. Due to its high polarity and short retention time, detecting and quantifying such phosphonate-containing drugs with LC/MS-based methods is challenging and requires derivatization with hazardous reagents. Given the emerging importance of phosphonate-containing drugs, developing a practical, accessible, and safe method for their quantitation in pharmacokinetics (PK) studies is desirable. NMR-based methods are often employed in drug discovery but are seldom used for compound quantitation in PK studies. Here, we show that proton-phosphorous (1H-31P) heteronuclear single quantum correlation (HSQC) NMR allows for quantitation of the phosphonate-containing enolase inhibitor HEX in plasma and tissue at micromolar concentrations. Although mice were shown to rapidly clear HEX from circulation (over 95% in <1 hr), the plasma half-life of HEX was more than 1hr in rats and nonhuman primates. This slower clearance rate affords a significantly higher exposure of HEX in rat models compared to mouse models while maintaining a favorable safety profile. Similar results were observed for the phosphonate-containing antibiotic, fosfomycin. Our study demonstrates the applicability of the 1H-31P HSQC method to quantify phosphonate-containing drugs in complex biological samples and illustrates an important limitation of mice as preclinical model species for phosphonate-containing drugs.
- organism: rat
- organism: non-human primate
- assay: metabolomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- High-throughput PBK modelling for dermal exposure: a pragmatic approach to predict systemic pharmacokinetics
Zeynep Edizcan, Stephan Schaller, … René Geci·Archives of ToxicologyPeer-reviewed·Mar 31, 2026
- Generic Purpose Pharmacokinetics-Pharmacodynamics Mathematical Model For Nanomedicine Targeted Drug Delivery: Mouse Model
Teddy Lazebnik, Hanna Weitman, Gal A. Kaminka·bioRxiv·Jul 13, 2022
- Developmental exposure to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) selectively decreases brain dopamine levels in northern leopard frogs
R. M. Foguth, R. W. Flynn, … J. Cannon·bioRxiv·May 6, 2019
- Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach
Jeffrey A. Mensah, Kristina J. Johnson, … Cameron S. Metcalf·EpilepsiaPeer-reviewed·Aug 29, 2022
- Aliphatic Amines are Viable Pro-drug Moieties in Phosphonoamidate Drugs
V. C. Yan, C.-D. Pham, … F. L. Muller·bioRxiv·Apr 5, 2020
- Pharmacokinetics of Sustained-Release Buprenorphine and Extended-Release Buprenorphine in Mice with Surgical Catheterization
M. Saenz, E. A. Bloom-Saldana, … J. B. Finlay·bioRxiv·Mar 14, 2022